GILD Stock Price Today (September 2026) — Gilead Sciences, Inc. Analysis & Key Metrics 2026-09-03
Gilead Sciences, Inc. (GILD) is trading at $151.22, up 1.08% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $157.15 (3.9% upside).
- Volatility remains elevated (23.23% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.20% YoY) alongside significant competitive pressures.
GILD Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Gilead Sciences, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $201.92B
P/E Ratio
Forward P/E: 14.80
Revenue Growth
Year over Year
Analyst Target
+3.9% upside potential
Key Investor Questions About GILD
What investors need to know before buying
Based on current market data, GILD presents a overbought technical setup with caution warranted fundamentals.
- Technicals say: Overbought (RSI 71.07)
- Fundamentals say: Caution warranted (high leverage concerns)
GILD's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for GILD investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $26.25B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, GILD stock traded between $108.46 and $157.29—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 23.23% annualized volatility and β=0.43, the stock exhibits low sensitivity to market moves—making GILD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Gilead Sciences Stock Outperforming the S&P 500?
Gilead Sciences has rallied the S&P 500 Index over the past year, and analysts remain highly bullish about the stock’s growth prospects.
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.
3 Unpopular Stocks with Open Questions
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
Gilead (GILD) Stock Looks Undervalued After A 147% Five Year Run
Gilead Sciences has delivered strong share price gains over the past five years, yet based on broad valuation checks it still screens as inexpensive relative to its fundamentals. For investors, the stock now sits in an interesting spot where a powerful HIV and oncology franchise is reflected in the price to some extent, but the broader valuation read still points to room for a more optimistic view than the market currently implies. Over the past 5 years, Gilead Sciences has returned about...
Explore More Analysis for GILD
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) is currently trading at $151.22. The RSI (14-day) is at 71.1, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $157.15 implies 3.9% upside from current levels. Volatility is moderate at 23.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Gilead Sciences, Inc. (GILD): The trailing P/E ratio is -57.06, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 14.80. Price-to-Book is 15.86. Price-to-Sales is 6.16. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 27 analysts covering GILD, the consensus price target is $157.15. This represents a 3.9% upside from the current price of $151.22. The range spans from a low target of $120.00 to a high target of $180.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Gilead Sciences, Inc. (GILD) pays a dividend with a current yield of approximately 2.17%. The annualized dividend rate is $3.22 per share. The payout ratio is 43.4%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-09-15T00:00:00.000Z.
Key risks for Gilead Sciences, Inc. (GILD) investors include: 1. Elevated debt levels (D/E ratio of 223.47) which could pressure margins in a rising rate environment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Gilead Sciences, Inc.'s (GILD) current debt and financial health profile: Total debt stands at $26.25B. The debt-to-equity ratio is 223.47, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.26, indicating adequate short-term liquidity. The quick ratio is 0.90. The company holds $4.88B in cash and equivalents. Free cash flow is positive at $9.77B, providing a cushion for debt servicing and shareholder returns.